Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user is using finasteride 1mg every other day and seeks a topical solution excluding minoxidil. They are considering various combinations of ingredients like finasteride, dutasteride, and tofacitinib, with options for nourishing oils and other additives.

A new hair growth spray in the UK contains finasteride 0.3%, minoxidil 5%, and tretinoin 0.01%, but some users find the finasteride concentration too high. Another brand offers a similar spray with a lower finasteride dose at a cheaper price, and some users report scalp irritation from the new spray.

Finasteride pills don't fully dissolve in a DIY topical solution due to fillers, resulting in residue. Users suggest shaking well before application and note that commercial solutions appear clearer.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Formula 82M, a minoxidil and retinol liquid, improved hair texture and filled in temples with baby hairs for the user, but its high cost and lack of reviews cause concern. Another user mentioned using a similar product, 82F, which has become less effective and expensive over time.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

The conversation is about the availability of the PP405 formula for hair loss treatment, with mentions of finasteride and its side effects. Users discuss the potential of obtaining the formula through unofficial channels and the challenges related to its genetic sequence and delivery method.

Choosing between KB and PG solutions for applying RU58841, considering factors like scalp oiliness and absorption. Some users prefer KB for being gentler, while others use PG and recommend washing hair before application for better results.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

Minoxidil sulfate is considered for those unresponsive to regular minoxidil, with some trying a 10% formulation from Folligenz. Concerns exist about the product's stability and transparency, but some users report positive initial results.

The user has been using topical melatonin spray with finasteride and dutasteride to reduce hair shedding but dislikes the lavender scent of their current spray. They are seeking recommendations for a scentless or better-smelling melatonin spray.

The user visited a trichologist due to ineffective topical finasteride treatment for hair loss. The trichologist recommended a new regimen including a two-month course of locoidon (cortisone 0.1%), followed by a solution containing minoxidil, hydrocortisone butirrate, estrone, progesterone, tocopherol acetate, trichosol, and transcutol.

A 19-year-old used a 0.01% topical finasteride formula, which unexpectedly lowered DHT levels significantly. They are considering reducing the dose further and exploring alternatives like ketoconazole shampoo, KX826, and CB to manage hair loss while minimizing systemic absorption.

The conversation discusses skepticism about the effectiveness of PP405 for hair loss, with users mentioning treatments like dutasteride, oral minoxidil, clascoterone, and upcoming drugs like breezula and long-release oral minoxidil. Some users express hope for future treatments like vdphl01 and amplifica, while others debate the effectiveness and side effects of current options.

The conversation discusses using CB0301/Clascoterone as a potential treatment for hair loss, especially for those experiencing side effects from finasteride and dutasteride. The user currently uses oral minoxidil and considers combining it with other treatments like kx826, DHT blocker supplements, and 2% Nizoral shampoo.

The conversation discusses switching from oral to topical finasteride due to side effects like nipple soreness. The user seeks advice on diluting and applying topical finasteride to minimize adverse effects.

A user with diffuse thinning recommends a root cover-up spray as a temporary, medication-free solution. They plan to consult a dermatologist for treatments like Minoxidil and finasteride while using the spray for special occasions.

The user is using a regimen of topical finasteride (.025% concentration), minoxidil, Nutrafol, and vitamin D to address hair loss. They experienced initial side effects but reported improvement over 11 weeks and are considering increasing the dosage.

Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

Topical finasteride that doesn't penetrate the skin could potentially treat hair loss without side effects. Current challenges include finding a formulation that remains on the scalp without increasing blood levels.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

Clascoterone (Breezula) is anticipated for release in the coming years but is considered too weak for aggressive androgenetic alopecia (AGA). Current treatments like minoxidil, finasteride, and dutasteride are preferred, with some users obtaining clascoterone from the gray market.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The user experienced severe scalp itching after using RU58841 and ketoconazole shampoo, despite trying moisturizing treatments. They suspect the issue is related to the propylene glycol in the vehicle and are seeking alternatives.

The user is happy with hair growth progress after using minoxidil foam and 1mg finasteride for over six months, despite initial scalp itching. They are considering switching to oral minoxidil for faster growth and are concerned about maintaining consistency with the foam application.

Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.

Using roll-on bottles for applying minoxidil and RU58841 improves application efficiency and reduces product waste. Topical treatments are used continuously, except on microneedling days.